Full Prescribing
Information
How Supplied
| NDC No. 63323- |
Product No. |
Description | Concentration | Strength | Vial Size/ Fill |
Closure | Pack Size |
Min. Direct Order Qty. |
| 285-65 | 278565 | SD
Infusion Bottle |
2 mg/mL | 0.20% | 100 mL | 28 mm | 1 | 12 x 1 |
| 285-64 | 278564 | SD
Infusion Bottle |
2 mg/mL | 0.20% | 200 mL | 28 mm | 1 | 12 x 1 |
| 285-10 | 278510 | Polyamp DuoFit® Sterile Pak |
2 mg/mL | 0.20% | 10 mL | N/A | 5 | 24 x 5 |
| 285-20 | 278520 | Polyamp DuoFit® Sterile Pak |
2 mg/mL | 0.20% | 20 mL | N/A | 5 | 20 x 5 |
| 286-20 | 278620 | Polyamp DuoFit® Sterile Pak |
5 mg/mL | 0.50% | 20 mL | N/A | 5 | 20 x 5 |
| 286-30 | 278630 | SD Vial | 5 mg/mL | 0.50% | 30 mL | 20 mm | 1 | 50 x 1 |
| 286-31 | 278631 | Sterile-Pak SD Vial |
5 mg/mL | 0.50% | 30 mL | 20 mm | 5 | 10 x 5 |
| 287-20 | 278720 | Polyamp DuoFit® Sterile Pak |
7.5 mg/mL | 0.75% | 20 mL | N/A | 5 | 20 x 5 |
| 288-10 | 278810 | Polyamp DuoFit® Sterile Pak |
10 mg/mL | 1% | 10 mL | N/A | 5 | 24 x 5 |
| 288-20 | 278820 | Polyamp DuoFit® Sterile Pak |
10 mg/mL | 1% | 20 mL | N/A | 5 | 20 x 5 |
|
BAR CODED • LATEX FREE • PRESERVATIVE FREE |
||||||||
Important Safety Information
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
®
Using NAROPIN beyond recommended doses to increase motor block or duration of sensory block may negate its favorable cardiovascular advantages, in the event that an inadvertent intravascular injection occurs.
Like all amide-type local anesthetics, NAROPIN may be associated with adverse reactions. In clinical trials, side effects were mild and transient and may reflect the procedures, patient health status, and/or other medications used. Adverse events reported at a rate of ≥5%: hypotension, nausea, vomiting, bradycardia, fever, pain, postoperative complications, anemia, paresthesia, headache, pruritus, and back pain.
New Safety Information
There have been adverse event reports of chondrolysis in patients receiving intra-articular infusions of local anesthetics following arthroscopic and other surgical procedures. NAROPIN is not approved for this use.
Please see Full Prescribing Information at www.naropin-us.com.
NAROPIN® and logo are registered trademarks of APP Pharmaceuticals, LLC.
®and APP® are registered trademarks of APP Pharmaceuticals, LLC.
©2010, APP Pharmaceuticals, LLC. All Rights Reserved.